title: Graft rejection after hematopoietic cell transplantation with nonmyeloablative conditioning.
abstract: Graft rejection after hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning is a rare but serious clinical problem. Graft rejection and salvage therapy in eight patients in a retrospective analysis of 124 consecutive patients is reported. The patients were conditioned with low-dose fludarabine and total body irradiation (TBI). The association of pretransplantation risk factors with rejection and the effect of chimerism and graft-versus-host disease on rejection were analyzed. Overall survival (OS) and progression free survival (PFS) were compared between patients with and without rejection. Retransplantation was performed with increased TBI conditioning for all patients, and with increased mycophenolate mofetil doses for recipients with HLA-identical sibling donors. No known pretransplantation risk factors were confirmed in this study. Rejection episodes were unevenly distributed over time. The storage temperature of the apheresis products was identified as a risk factor for rejection. Storage of the apheresis products at 5 degrees C diminished the risk of rejection. Low donor T cell chimerism at Day +14 significantly increased the risk of rejection. Seven patients were retransplanted. All but one engrafted successfully, but with decreased OS and PFS. Two patients received pentostatin infusion prior to donor lymphocyte infusions in unsuccessful attempts at reversing rejection. Storage temperature and donor chimerism had a significant effect on rejection. Following rejection, patients are at greater risk of dying from infections and progression/relapse of their malignancy. Retransplantation is feasible and well tolerated after HCT with nonmyeloablative conditioning and should be performed without delay in patients with imminent and manifest graft rejection.
authors.affiliation: Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen, Denmark. masmas@dadlnet.dk
authors.forename: Tania N
authors.initials: TN
authors.lastname: Masmas
authors.forename: Søren L
authors.initials: SL
authors.lastname: Petersen
authors.forename: Hans O
authors.initials: HO
authors.lastname: Madsen
authors.forename: Lars P
authors.initials: LP
authors.lastname: Ryder
authors.forename: Brian
authors.initials: B
authors.lastname: Kornblit
authors.forename: Arne
authors.initials: A
authors.lastname: Svejgaard
authors.forename: Pernille
authors.initials: P
authors.lastname: Andersen
authors.forename: Ebbe
authors.initials: E
authors.lastname: Dickmeiss
authors.forename: Lars L
authors.initials: LL
authors.lastname: Vindeløv
mesh_terms: D046528:Chimerism; D006084:Graft Rejection / Q000276:immunology*; D042381:Granulocyte Precursor Cells / Q000166:cytology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D012307:Risk Factors; D013997:Time Factors; D019172:Transplantation Conditioning; D016896:Treatment Outcome